Sanovel, a prominent player within regional pharmaceutical manufacturing, advanced R&D formulations, and global healthcare supply chains, has restructured its executive committee to support its corporate transformation strategy. To optimize its international investment portfolios, cross-border asset management, and complex financial operations, the enterprise has appointed industry veteran Gökdeniz Gür as its new Chief Financial Officer (CFO). Effectively stepping into his executive role as of June 2026, Gür will oversee the financial planning, auditing metrics, and fiscal efficiency models behind Sanovel’s multi-market footprint spanning five continents.
Gökdeniz Gür: Composing a 30-Year Multifunctional Financial and Strategic Career
With a professional tenure approaching three decades, Gür has built extensive administrative expertise across diverse sectors, including healthcare networks, heavy manufacturing, real estate investment trusts (REITs), hospitality, and corporate advisory services.
His verified professional track and academic credentials contain the following milestones:
Academic Foundations: Graduated with a bachelor's degree from the Department of Economics at Bilkent University.
Corporate Inception and PwC Auditing: Commenced his career loop in 1995 within the banking network at Garanti Bank before transitioning to global professional services leader PwC (PriceWaterhouseCoopers). At PwC, he successfully managed comprehensive audit tracks and financial advisory operations for multinational enterprises.
C-Suite Financial Steering: Served as CFO for Akfen REIT and Turcotel (a strategic subsidiary of TUI AG), while subsequently deploying his skills as a Financial Strategy Consultant for Hidromek and Strategic Planning Director at Beyçelik Holding.
Healthcare Operations Management (2019-2025): Prior to joining Sanovel, he functioned as the Vice President of Corporate Productivity and Internal Audit at Florence Nightingale Hospitals from 2019 to 2025. Over this six-year period, he successfully engineered internal financial controllership standards, streamlined operational cost structures, and modernized enterprise resource reporting lines.
An Industrial Pharmaceutical Powerhouse: The Sanovel Footprint
Established in 1983 by Pharmacist Erol Toksöz and sustained today by a specialized workforce of approximately 2,000 employees, Sanovel is recognized as an export leader within the regional jenerik drug production sectors. The industrial assets and quality indices that the updated CFO framework will structurally fund include:
Output and Portfolio Density: Holding a robust intellectual property and molecule catalog of more than 60 brands and 180 distinct products, the entity commands an annual manufacturing volume of 200 million units.
Global Regulatory Compliances: Sanovel’s high-tech production complexes run under certified European cGMP (Current Good Manufacturing Practice) standards and carry the definitive validation seal of the United States Food and Drug Administration (FDA).
Export Velocity: Operating as a first-to-market pioneer across various therapeutic jenerik classifications, Sanovel ships its primary formulations to more than 50 sovereign nations across 5 continents, accelerating its cross-border brand equity daily.
In his new role, CFO Gökdeniz Gür will optimize Sanovel's capital allocation strategies, production cost variables, and corporate reporting lines while delivering data-driven direction to the company's sustainable global expansion plans and multi-market commercial operations.
